Patents by Inventor Lutz Jermutus

Lutz Jermutus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human Antibody Molecules For IL-13
    Publication number: 20120052060
    Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Application
    Filed: November 8, 2010
    Publication date: March 1, 2012
    Applicant: MedImmune Limited
    Inventors: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter
  • Human antibody molecules for IL-13
    Patent number: 7947273
    Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Grant
    Filed: June 25, 2007
    Date of Patent: May 24, 2011
    Assignee: MedImmune Limited
    Inventors: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter
  • Human antibody molecules for IL-13
    Patent number: 7829090
    Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: November 9, 2010
    Assignee: MedImmune Limited
    Inventors: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter
  • Human antibody molecules for IL-13
    Publication number: 20090123478
    Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Application
    Filed: June 25, 2007
    Publication date: May 14, 2009
    Inventors: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter
  • Erythropoietin Protein Variants
    Publication number: 20080194475
    Abstract: Erythropoietin (EPO) variants, in particular variants that have improved stability, their manufacture and use, for example in therapy.
    Type: Application
    Filed: April 22, 2005
    Publication date: August 14, 2008
    Inventors: Andrew Buchanan, Lutz Jermutus
  • Ribosome Display or Mrna Display Method With Selection for Increased Stability of the Protein
    Publication number: 20070298430
    Abstract: A method of providing a subject polypeptide variant with improved stability compared with a parent subject polypeptide, employing translation and selection using an RNA expression system, wherein two or more stability selection pressures are applied simultaneously during translation, two or more stability selection pressures are applied simultaneously during selecting, or at least one stability selection pressure is applied during translation and continues to be applied during selecting, and at least one further stability selection pressure is applied during selecting.
    Type: Application
    Filed: January 5, 2006
    Publication date: December 27, 2007
    Inventors: Andrew Buchanan, Lutz Jermutus
  • Antibodies to TGF-beta
    Publication number: 20070264255
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Application
    Filed: January 30, 2007
    Publication date: November 15, 2007
    Inventors: Steven Ledbetter, Celia Hart, Robert Holgate, Lutz Jermutus, Catriona Buchanan, Alexander Duncan, Donna Finch
  • Antibodies to TGF-BETA
    Publication number: 20070134246
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Application
    Filed: January 30, 2007
    Publication date: June 14, 2007
    Inventors: Steven Ledbetter, Celia Hart, Robert Holgate, Lutz Jermutus, Catriona Buchanan, Alexander Duncan, Donna Finch
  • Human antibody molecules for il-13
    Publication number: 20070128192
    Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Application
    Filed: July 15, 2004
    Publication date: June 7, 2007
    Applicant: CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED
    Inventors: Philip Monk, Lutz Jermutus, Ceila Shorrock, Ralph Minter
  • Antibodies to TGF-beta
    Publication number: 20060251658
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Application
    Filed: February 8, 2006
    Publication date: November 9, 2006
    Inventors: Steven Ledbetter, Celia Hart, Robert Holgate, Lutz Jermutus, Catriona Buchanan, Alexander Duncan, Donna Finch
  • Methods and means relating to protein variants
    Publication number: 20060183200
    Abstract: A method of providing a subject polypeptide variant with improved stability compared with a parent subject polypeptide, employing translation and selection using an RNA expression system, wherein two or more stability selection pressures are applied simultaneously during translation, two or more stability selection pressures are applied simultaneously during selecting, or at least one stability selection pressure is applied during translation and continues to be applied during selecting, and at least one further stability selection pressure is applied during selecting.
    Type: Application
    Filed: January 5, 2006
    Publication date: August 17, 2006
    Inventors: Andrew Buchanan, Lutz Jermutus
  • Human antibody molecules for IL-13
    Publication number: 20050065327
    Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis,.fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Application
    Filed: July 15, 2004
    Publication date: March 24, 2005
    Inventors: Phillip Monk, Lutz Jermutus, Celia Shorrock, Ralph Minter
  • Polysome display in the absence of functional ssrA-RNA
    Patent number: 6589741
    Abstract: The present invention relates to methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules. The method of the present invention is particularly characterized by an in vitro translation step under conditions that allow formation of polysomes in the presence of antisense oligonucleotides complementary to the tag-coding sequence of ssrA-RNA. The present invention further relates to kits that are useful for carrying out the method of the invention.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: July 8, 2003
    Assignee: University of Zurich
    Inventors: Andreas Plückthun, Jozef Hanes, Lutz Jermutus
  • Novel methods for identifying nucleic acid molecules encoding (poly) peptides that interact with target molecules
    Publication number: 20020115083
    Abstract: The present invention relates to methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules. The method of the present invention is particularly characterized by an in vitro translation step under conditions that allow formation of polysomes in the presence of antisense oligonucleotides complementary to the tag-coding sequence of ssrA-RNA. The present invention further relates to kits that are useful for carrying out the method of the invention.
    Type: Application
    Filed: September 14, 2001
    Publication date: August 22, 2002
    Inventors: Andreas Pluckthun, Jozef Hanes, Lutz Jermutus
  • Polysome display in the absence of functional ssrA-RNA
    Patent number: 6348315
    Abstract: The present invention relates to methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules. The method of the present invention is particularly characterized by an in vitro translation step under conditions that allow formation of polysomes in the presence of antisense oligonucleotides complementary to the tag-coding sequence of ssrA-RNA. The present invention further relates to kits that are useful for carrying out the method of the invention.
    Type: Grant
    Filed: October 22, 1999
    Date of Patent: February 19, 2002
    Assignee: University of Zürich, Assignee for Josef Hanes
    Inventors: Andreas Plückthun, Jozef Hanes, Lutz Jermutus